ProfileGDS5678 / 1449240_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 56% 56% 54% 55% 59% 57% 55% 56% 55% 56% 55% 56% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5192858
GSM967853U87-EV human glioblastoma xenograft - Control 23.3938256
GSM967854U87-EV human glioblastoma xenograft - Control 33.401656
GSM967855U87-EV human glioblastoma xenograft - Control 43.2665654
GSM967856U87-EV human glioblastoma xenograft - Control 53.3094455
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6435359
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5602357
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3857355
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.385856
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3575155
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.39956
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3274855
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4449556
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4045656